From the Research
Delta Sleep-Inducing Peptide (DSIP) can be absorbed orally, as evidenced by a study in neonatal rats where significant increases in plasma DSIP-like immunoreactivity occurred after oral administration of an analog of DSIP. This finding suggests that DSIP or its analogs may be able to cross the gastrointestinal tract and enter the systemic circulation when taken orally. However, it's essential to consider the context and species of the study, as the absorption and bioavailability of DSIP in humans may differ.
The study published in Life Sciences in 1983 1 demonstrated that DSIP-like material is absorbed by the gastrointestinal tract of neonatal rats, with significant increases in plasma DSIP-like immunoreactivity after oral administration of an analog of DSIP. This study provides evidence that DSIP can be absorbed orally, at least in neonatal rats.
In contrast to the example answers provided, which suggest that DSIP is not effectively absorbed when taken orally, the study by 1 indicates that oral absorption of DSIP is possible. However, it's crucial to note that the bioavailability and efficacy of orally administered DSIP in humans may be limited due to degradation by digestive enzymes.
Key points to consider:
- DSIP can be absorbed orally in neonatal rats, as shown by increased plasma DSIP-like immunoreactivity after oral administration of an analog of DSIP 1.
- The bioavailability and efficacy of orally administered DSIP in humans may be limited due to degradation by digestive enzymes.
- Alternative delivery methods, such as injection, may be necessary to achieve therapeutic levels of DSIP in the brain.
Overall, while the evidence suggests that DSIP can be absorbed orally, its effectiveness and bioavailability in humans require further investigation. Based on the available evidence, oral administration of DSIP may be a viable option, but its efficacy and safety in humans need to be established through further research.